Mucinous cancer of the appendix: challenges in diagnosis and treatment.

Mucinous cancer of the appendix: challenges in diagnosis and treatment. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Mucinous cancer of the appendix: challenges in diagnosis and treatment. Abstract Text:

E Andreopoulou,H Yee,M A Warycha,M Macari,R Berman,A Lowy,F Muggia,

The authors report and discuss a case of a mucinous carcinoma of the appendix, a rare entity with a distinct natural history that poses diagnostic and therapeutic challenges. Mucinous peritoneal carcinomatosis is most commonly associated with primary tumors of the appendix and colon. Typically, spread remains confined to the abdominal cavity. Imaging assessment of these mucinous lesions is difficult, while tumor markers (CEA and CA19.9) may be surrogates for extent of disease. Treatment consists of surgical debulking, sometimes coupled with intraperitoneal drug delivery, but recurrence is universal. New treatment approaches are needed. Mucin genes are regulated in part by epidermal growth factor receptor signaling. Therefore, we initiated a phase II study of cetuximab for mucinous peritoneal carcinomatosis, that was part of this patient's treatment.

Mucinous cancer of the appendix: challenges in diagnosis and treatment. Publishing Authors By Initials

E Andreopoulou,H Yee,MA Warycha,M Macari,R Berman,A Lowy,F Muggia,

For similar animals: chordata: vertebrates: mammals: primates: haplorhini: catarrhini: hominidae: humans research abstracts see: animals: chordata: vertebrates: mammals: primates: haplorhini: catarrhini: hominidae: humans research

PUBMED ID PMID:

MEDLINE DATE:

Mucinous cancer of the appendix: challenges in diagnosis and treatment. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of chemotherapy (Florence, Italy)

VOLUME: 19

Page Numbers: 451-4

Journal Abbreviation:

ISSN: 1120-009X

DAY: 3

MONTH: Aug

YEAR: 2007

Mucinous cancer of the appendix: challenges in diagnosis and treatment. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8907348

Mucinous cancer of the appendix: challenges in diagnosis and treatment. Keywords Mesh Terms:

KEYWORDS: Humans

MESH TERMS: analysis

Chemical & Substance for Abstract: Mucinous cancer of the appendix: challenges in diagnosis and treatment. Information

Substance Name: Carcinoembryonic Antigen

Registry Number: 0

Grant and Affiliation Information for Mucinous cancer of the appendix: challenges in diagnosis and treatment.

AFFILIATION: Department of Medicine, New York University School of Medicine, New York, NY, USA. andree02@med.nyu.edu

Country: Italy

AGENCY: United States NCI

GRANT: T32CA09454

ACRONYM: CA

MEDLINETA: J Chemother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Mucinous cancer of the appendix: challenges in diagnosis and treatment Related Publications

• Brain metastases from choriocarcinoma: two patients illustrating key management issues.
• Chemo- and immunopharmacology: the reality and the horizons of cancer treatment.
• Clinical evaluation of new antitumor antibiotics.
• Correlation of histologic types with cell kinetic studies in lung cancer.
• Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
• Hormonal management of breast cancer.
• Long-term sequelae of cancer chemotherapy.
• Mucinous cancer of the appendix: challenges in diagnosis and treatment.
• N-(Phosphonacetyl)-L-aspartate (PALA): current status.
• Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer.
• Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes.
• Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity.
• The rediscovery of DON (6-diazo-5-oxo-L-norleucine).
• Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.
• Treatment of advanced Hodgkin's disease with vinblastine (NSC-49842) or procarbazine (NSC-77213).
• Treatment of malignant brain tumors with nitrosoureas.
• [Not Available.]
• [Not Available.]
• [Not Available.]
• m-AMSA: a new anticancer agent.